Indian pharma major Cipla today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza for treatment of o treat mild to moderate COVID-19 patients. Cipla will commercially launch Ciplenza in the first week of August priced at ₹68 per tablet.
Favipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID-19 patients with mild to moderate symptoms, Cipla said.
To ensure fair and equitable distribution of the drug", Cipla said supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.
The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use, Cipla said.
No comments:
Post a Comment